pufa 20:3 n-6

PUFA 20:3 n‑6, also known as dihomo‑γ‑linolenic acid (DGLA), is a 20‑carbon omega‑6 polyunsaturated fatty acid characterized by three cis double bonds at carbon positions 8, 11, and 14. Structurally, it is a metabolic elongation product of gamma‑linolenic acid (GLA) and a downstream metabolite of linoleic acid, the common essential omega‑6 fatty acid in most Western diets. While linoleic acid and α‑linolenic acid are considered essential because they cannot be synthesized by humans, DGLA itself is normally synthesized endogenously via enzyme pathways involving Δ6 desaturase and elongase enzymes. In physiological literature, DGLA is recognized for its potential role in cell membrane composition and as a substrate for eicosanoid production. Unlike more abundant polyunsaturated fatty acids such as arachidonic acid (20:4 n‑6), or long‑chain n‑3 fatty acids EPA (20:5 n‑3) and DHA (22:6 n‑3), DGLA is typically found in very low (trace) proportions in tissues, and dietary intake of DGLA itself is negligible. Instead, dietary precursors such as γ‑linolenic acid from select plant oils contribute indirectly to tissue levels of DGLA, as they can be desaturated and elongated in vivo. The scientific literature defines DGLA as a structural component of cell membranes that influences the production of certain eicosanoids—bioactive lipid mediators that impact inflammation, immune responses, and vascular function. Research explores how DGLA competes with arachidonic acid for enzymatic conversion by cyclooxygenase and lipoxygenase pathways, potentially shifting the balance of eicosanoids toward less pro‑inflammatory prostaglandins like PGE1. Although the metabolic context and balance with other fatty acids are important determinants of physiological effects, DGLA is not considered an essential nutrient in its own right because it is typically synthesized from dietary linoleic acid through gamma‑linolenic acid intermediates. Therefore, nutritional guidelines focus on essential fatty acids upstream of DGLA rather than recommending a specific intake of PUFA 20:3 n‑6 itself.

DGLA plays a nuanced role in human biochemistry primarily through its influence on eicosanoid production and cell membrane dynamics. As an omega‑6 fatty acid, it serves as a precursor for series‑1 prostaglandins, such as prostaglandin E1 (PGE1), which exhibit vasodilatory and antithrombotic properties. Unlike the more pro‑inflammatory series‑2 prostaglandins derived from arachidonic acid (20:4 n‑6), DGLA‑derived mediators may support a more balanced inflammatory milieu. Biochemical research indicates that DGLA competes with arachidonic acid for cyclooxygenase and lipoxygenase enzymes, thereby favoring production of eicosanoids with weaker inflammatory actions and potentially reducing the synthesis of pro‑aggregatory thromboxanes. At the cellular level, DGLA incorporation into membrane phospholipids can alter membrane fluidity and receptor functioning, which influences immune cell signaling and endothelial responses. Experimental in vitro studies have shown that DGLA can modulate macrophage activity and attenuate expression of inflammatory mediators such as MCP‑1 and ICAM‑1, indicating a potential role in immunomodulation. In animal models, modulation of DGLA levels has been associated with changes in atherosclerotic plaque development, suggesting potential cardiovascular implications, although direct evidence in humans remains limited. Specifically, research in mouse models demonstrated that DGLA supplementation attenuated processes linked to atherosclerosis, supporting hypotheses regarding vascular health benefits. The balance between omega‑6 and omega‑3 fatty acids, rather than absolute levels of DGLA alone, is considered critical for optimal health outcomes. A lower dietary n‑6/n‑3 ratio has been associated with improved lipid metabolism and reduced inflammatory markers in clinical contexts. While DGLA itself is not a target of dietary recommendations, its metabolic pathways intersect with mechanisms implicated in cardiovascular health, inflammatory disorders, and metabolic regulation. Clinical research emphasizes that dietary patterns rich in essential precursors and balanced in polyunsaturated fats foster a favorable environment for producing beneficial lipid mediators, although the direct health effects of DGLA in humans require further rigorous study.

Unlike essential nutrients with established Dietary Reference Intakes, there are no specific daily intake recommendations for DGLA. This is because the human body typically synthesizes DGLA endogenously from linoleic acid via gamma‑linolenic acid intermediates and because dietary intake of DGLA itself is extremely low. The NIH Office of Dietary Supplements does not provide RDAs or Adequate Intakes for DGLA, and authoritative bodies focus instead on essential fatty acids upstream of DGLA, particularly linoleic acid (LA) and α‑linolenic acid (ALA). NIHs Dietary Reference Intakes specify a total linoleic acid intake of about 17 g/day for adult males and 12 g/day for adult females to meet essential fatty acid requirements, which indirectly supports downstream production of longer chain metabolites including DGLA. Factors affecting endogenous DGLA production include the efficiency of desaturase and elongase enzymes, nutritional cofactors such as vitamins and minerals, and the overall balance of dietary polyunsaturated fats. Genetic variations in fatty acid desaturase enzymes can influence an individual’s capacity to produce DGLA from precursors. Because of these factors, some individuals might produce more or less DGLA for a given intake of precursors. Optimal levels of DGLA have not been defined, and there are no established deficiency thresholds or target blood levels. In clinical settings where fatty acid profiles are measured, interpretation centers on overall balance among PUFAs rather than DGLA alone. Therefore, public health guidance emphasizes achieving adequate intake of linoleic acid and maintaining a balanced ratio of omega‑6 to omega‑3 fatty acids as part of a healthful dietary pattern.

Because DGLA is not considered an essential nutrient itself, there is no defined clinical deficiency syndrome attributable solely to inadequate intake of DGLA. Instead, deficiency of its precursor, linoleic acid, leads to essential fatty acid deficiency, which can manifest in symptoms such as dry, scaly skin, poor wound healing, increased susceptibility to infection, and slowed growth in infants. When linoleic acid intake is extremely low, tissue levels of downstream metabolites including γ‑linolenic acid and DGLA may be reduced. In such contexts, clinicians may observe abnormalities in plasma fatty acid profiles and impaired production of lipid mediators. However, specific clinical signs attributed to DGLA deficiency have not been delineated in authoritative sources. Blood fatty acid testing can measure levels of DGLA as part of a broader lipid panel, and low DGLA in the context of an imbalance with arachidonic acid might reflect altered enzymatic activity or insufficient precursor availability. At‑risk populations for low DGLA due to precursor limitations include individuals with poor dietary intake of essential fatty acids, those with genetic variants affecting desaturase enzymes, and people with disorders affecting fat absorption. Nonetheless, isolated low DGLA without concomitant essential fatty acid deficiency is rare and not well documented as a primary clinical condition.

Because DGLA itself is present in trace amounts in most foods, direct dietary sources are limited, and quantitative data on DGLA content in foods are scarce. Instead, nutrition science focuses on foods containing its metabolic precursor γ‑linolenic acid (GLA), which the body can convert to DGLA. Plant seed oils such as borage oil, evening primrose oil, blackcurrant seed oil, and hemp seed oil are among the richest dietary sources of GLA. Borage oil typically contains approximately 18–26% GLA by weight, evening primrose oil around 8–10%, and blackcurrant seed oil 15–20%, providing substrates that may enhance DGLA production. Other foods containing smaller amounts of GLA include spirulina, oats, barley, and select nuts and seeds. For example, hemp seeds also provide a balance of polyunsaturated fats including precursors of DGLA. Dietary intake of linoleic acid, abundant in common vegetable oils such as safflower, sunflower, corn, and soybean oils, supports essential fatty acid status and ultimately DGLA synthesis. Quantifying specific amounts of DGLA in typical food servings is challenging because levels tend to be extremely low or not routinely reported in nutrient databases. Nonetheless, including foods rich in essential linoleic acid and GLA precursors can support tissue levels of DGLA and related eicosanoids. The food sources table below lists common and unusual foods with approximate precursor values that reflect potential for downstream DGLA production.

Like other polyunsaturated fatty acids, DGLA is absorbed in the small intestine along with dietary fats. After micellar incorporation, it is taken up by enterocytes and packaged into chylomicrons for transport through the lymphatic system into circulation. Within tissues, DGLA becomes incorporated into phospholipids of cell membranes, where its presence can alter membrane fluidity and function. Because direct dietary intake of DGLA is minimal, bioavailability in humans depends on the availability of metabolic precursors such as GLA and the efficiency of conversion enzymes. Factors that enhance absorption and utilization of DGLA and its precursors include concurrent intake of other dietary fats, which stimulate bile release and micelle formation, and the presence of cofactors such as vitamins and minerals necessary for enzyme activity. Conversely, high intake of trans fats and imbalanced omega‑3 to omega‑6 ratios may impair metabolism. Timing of intake with meals high in fat may improve absorption compared with low‑fat contexts. Because DGLA is integrated into broader fatty acid metabolism, its bioavailability is best understood in the context of overall polyunsaturated fat digestion and transport.

Supplements marketed specifically for DGLA are uncommon because DGLA is not considered essential and typical diets provide negligible direct amounts. Instead, supplements containing γ‑linolenic acid (such as borage oil, evening primrose oil, and blackcurrant seed oil) are used with the aim of enhancing downstream DGLA production. Some clinical trials have evaluated GLA supplementation for conditions like atopic dermatitis and rheumatoid arthritis, with mixed results, and benefits might be linked to modulation of eicosanoid pathways rather than DGLA per se. When considering supplementation, patients should consult healthcare professionals, particularly because supplemental fats can interact with medications and affect lipid profiles. People with rheumatoid arthritis, eczema, or other inflammatory conditions sometimes use GLA supplements under clinical guidance, but evidence is not definitive. Quality considerations include ensuring products are free of oxidation products and contaminants. Because DGLA metabolism intersects with broader fatty acid pathways, a balanced omega‑6 to omega‑3 ratio is also important to avoid promoting pro‑inflammatory states. Supplements in the form of GLA often recommend doses standardized by GLA content rather than direct DGLA, and dosing must account for individual health status and concomitant nutrient status. As always, focus should remain on achieving a healthful diet before resorting to supplementation.

There are no defined tolerable upper intake limits for DGLA or its precursors, reflecting a lack of evidence for toxicity at typical dietary levels. Because DGLA is produced endogenously and dietary intake is minimal, adverse effects from DGLA itself have not been characterized by authoritative bodies. However, excessive intake of omega‑6 fats in general, particularly in the context of very high linoleic acid intake and poor balance with omega‑3 fats, may contribute to unfavorable inflammatory profiles and lipid mediator shifts, although this is debated. Supplements containing high doses of γ‑linolenic acid or other fatty acids may increase the risk of gastrointestinal symptoms or bleeding tendencies in susceptible individuals, especially those on anticoagulants. Therefore, individuals taking such supplements should do so under medical supervision.

Because DGLA itself is a fatty acid metabolite, direct drug interactions are uncommon. However, supplements containing high levels of polyunsaturated fats, including γ‑linolenic acid precursors, may interact with medications that affect bleeding risk, such as warfarin or antiplatelet drugs, by altering platelet aggregation pathways. Polyunsaturated fatty acids can modulate the effects of cyclooxygenase enzymes that are targets of NSAIDs, potentially influencing inflammatory responses. Patients on lipid‑lowering medications should discuss use of fatty acid supplements with clinicians to avoid unintended effects on lipid profiles. Always consult healthcare providers before combining supplements with prescription medications.

Common Forms: Borage oil, Evening primrose oil, Blackcurrant seed oil

Typical Doses: 500–1000 mg GLA precursors daily (not DGLA directly)

When to Take: With meals high in fats to enhance absorption

Best Form: Triglyceride oil form with antioxidants

⚠️ Interactions: Anticoagulants like warfarin, Antiplatelet drugs